NCT01912534View on ClinicalTrials.gov

Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM

PHASE2CompletedINTERVENTIONAL
Enrollment

211

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2019

Conditions
Hypertrophic Cardiomyopathy
Interventions
DRUG

Valsartan

40, 80 and 160 mg tablets of Valsartan

DRUG

Placebo

During Active Run-In, all patients take Valsartan. During maintenance, all patients are randomized to valsartan or placebo

Trial Locations (15)

19104

Children's Hospital of Philadelphia, Philadelphia

University of Pennsylvania, Philadelphia

21287

Johns Hopkins University, Baltimore

37232

Vanderbilt University, Nashville

44195

Cleveland Clinic Foundation, Cleveland

45229

Cinncinnati Children's Hospital Medical Center, Cincinnati

48109

University of Michigan, Ann Arbor

60637

University of Chicago, Chicago

63110

Washington University School Medicine, St Louis

80045

University of Colorado, Aurora

94305

Stanford University, Stanford

02115

Brigham & Women's Hospital, Boston

Children's Hospital Boston, Boston

M4W3S5

Toronto General Hospital, Toronto

M5G1X8

Toronto Sick Kids, Toronto

Sponsors

Lead Sponsor

Carelon Research
All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Carelon Research

OTHER